Cyclomune is an ophthalmic solution that contains cyclosporine as its active component. Cyclosporine belongs to the class of immunosuppressants and is used in the management of ocular surface disorders that involve inflammation. In Hong Kong, Cyclomune is a prescription-only medication regulated by the Department of Health. It is supplied in a bottle of ophthalmic solution, with two authorized strengths: 0.05 % and 0.1 %.
Cyclosporine is a calcineurin inhibitor. By binding to cyclophilin inside T-lymphocytes, it blocks the enzyme calcineurin, which is essential for activating the transcription factor NF-κB. This inhibition reduces the production of inflammatory cytokines such as interleukin-2, leading to decreased T-cell activation and inflammation on the ocular surface.
Cyclomune is approved in Hong Kong for the treatment of dry eye disease (keratoconjunctivitis sicca), an autoimmune-mediated condition characterized by tear-film instability and ocular surface inflammation. It is indicated for patients who have persistent symptoms despite the use of artificial tears.
If further therapeutic applications are explored, they must be supported by peer-reviewed evidence and are considered off-label.
No robust, peer-reviewed evidence currently supports off-label uses of Cyclomune in Hong Kong. Consequently, this section is omitted to avoid speculation.
If detailed interaction data are unavailable, patients should always discuss their full medication list with a pharmacist or ophthalmologist.
This article provides educational information about Cyclomune and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes. Cyclomune is classified as a prescription ophthalmic medication, not a controlled substance, so it can be carried in hand luggage. Keep the bottle in its original packaging and present the prescription label if requested at security.
While all cyclosporine ophthalmic solutions share the same active ingredient, formulation differences (e.g., preservative type, vehicle viscosity) can affect tolerability. Cyclomune’s bottle format and available strengths (0.05 % and 0.1 %) provide flexibility for clinicians to tailor therapy based on disease severity.
Cyclomune is supplied in a clear, opaque-white ophthalmic bottle with a dropper tip. The label displays the product name, concentration (0.05 % or 0.1 %), and regulatory information required in Hong Kong.
It is advisable to remove contact lenses before instilling the drops and wait at least 15 minutes before reinserting them. This reduces the risk of lens contamination and ensures optimal drug absorption.
Cyclosporine is listed on the World Anti-Doping Agency (WADA) prohibited list when used systemically. Topical ocular use is generally considered a low-risk route, but athletes should disclose all medications to their sports governing body.
Pivotal Phase III studies demonstrated that twice-daily cyclosporine ophthalmic solution improved corneal staining scores and patient-reported symptoms compared with placebo. These trials formed the basis for regulatory approval for dry eye disease.
No. Storing the bottle at temperatures below room temperature can alter the solution’s viscosity and potency. Keep it at ambient conditions as indicated on the label.
After opening, the solution should be discarded after 30 days to minimize the risk of microbial growth, even if the printed expiration date is later.
A brief period of blurred vision or visual “cloudiness” can occur for a few minutes after instillation. This is normal and typically resolves without intervention.
The higher concentration may be prescribed for patients with more severe dry-eye signs or those who have not responded adequately to the lower strength. The clinician decides based on clinical assessment and tolerability.
